Literature DB >> 27254810

Developing a Very Low Vision Orientation and Mobility Test Battery (O&M-VLV).

Robert P Finger1, Lauren N Ayton, Lil Deverell, Fleur O'Hare, Shane C McSweeney, Chi D Luu, Eva K Fenwick, Jill E Keeffe, Robyn H Guymer, Sharon A Bentley.   

Abstract

PURPOSE: This study aimed to determine the feasibility of an assessment of vision-related orientation and mobility (O&M) tasks in persons with severe vision loss. These tasks may be used for future low vision rehabilitation clinical assessments or as outcome measures in vision restoration trials.
METHODS: Forty legally blind persons (mean visual acuity logMAR 2.3, or hand movements) with advanced retinitis pigmentosa participated in the Orientation & Mobility-Very Low Vision (O&M-VLV) subtests from the Low Vision Assessment of Daily Activities (LoVADA) protocol. Four categories of tasks were evaluated: route travel in three indoor hospital environments, a room orientation task (the "cafe"), a visual exploration task (the "gallery"), and a modified version of the Timed Up and Go (TUG) test, which assesses re-orientation and route travel. Spatial cognition was assessed using the Stuart Tactile Maps test. Visual acuity and visual fields were measured.
RESULTS: A generalized linear regression model showed that a number of measures in the O&amp;M-VLV tasks were related to residual visual function. The percentage of preferred walking speed without an aid on three travel routes was associated with visual field (p < 0.01 for all routes) whereas the number of contacts with obstacles during route travel was associated with acuity (p = 0.001). TUG-LV task time was associated with acuity (p = 0.003), as was the cafe time and distance traveled (p = 0.006 and p < 0.001, respectively). The gallery score was the only measure that was significantly associated with both residual acuity and fields (p < 0.001 and p = 0.001, respectively).
CONCLUSIONS: The O&amp;M-VLV was designed to capture key elements of O&amp;M performance in persons with severe vision loss, which is a population not often studied previously. Performance on these tasks was associated with both binocular visual acuity and visual field. This new protocol includes assessments of orientation, which may be of benefit in vision restoration clinical trials.

Entities:  

Mesh:

Year:  2016        PMID: 27254810     DOI: 10.1097/OPX.0000000000000891

Source DB:  PubMed          Journal:  Optom Vis Sci        ISSN: 1040-5488            Impact factor:   1.973


  10 in total

1.  Mobility test to assess functional vision in dark-adapted patients with Leber congenital amaurosis.

Authors:  Alejandro J Roman; Artur V Cideciyan; Vivian Wu; Abraham A Mascio; Arun K Krishnan; Alexandra V Garafalo; Samuel G Jacobson
Journal:  BMC Ophthalmol       Date:  2022-06-14       Impact factor: 2.086

2.  Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce.

Authors:  Lauren N Ayton; Joseph F Rizzo; Ian L Bailey; August Colenbrander; Gislin Dagnelie; Duane R Geruschat; Philip C Hessburg; Chris D McCarthy; Matthew A Petoe; Gary S Rubin; Philip R Troyk
Journal:  Transl Vis Sci Technol       Date:  2020-07-16       Impact factor: 3.283

Review 3.  An update on retinal prostheses.

Authors:  Lauren N Ayton; Nick Barnes; Gislin Dagnelie; Takashi Fujikado; Georges Goetz; Ralf Hornig; Bryan W Jones; Mahiul M K Muqit; Daniel L Rathbun; Katarina Stingl; James D Weiland; Matthew A Petoe
Journal:  Clin Neurophysiol       Date:  2019-12-10       Impact factor: 3.708

4.  Optimising technology to measure functional vision, mobility and service outcomes for people with low vision or blindness: protocol for a prospective cohort study in Australia and Malaysia.

Authors:  Lil Deverell; Denny Meyer; Bee Theng Lau; Abdullah Al Mahmud; Suku Sukunesan; Jahar Bhowmik; Almon Chai; Chris McCarthy; Pan Zheng; Andrew Pipingas; Fakir M Amirul Islam
Journal:  BMJ Open       Date:  2017-12-21       Impact factor: 2.692

5.  Validation of a vision-related activity scale for patients with retinitis pigmentosa.

Authors:  Francisco M Costela; Konrad Pesudovs; Michael A Sandberg; Carol Weigel-DiFranco; Russell L Woods
Journal:  Health Qual Life Outcomes       Date:  2020-06-22       Impact factor: 3.186

6.  A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: Interim Clinical Trial Results.

Authors:  Matthew A Petoe; Samuel A Titchener; Maria Kolic; William G Kentler; Carla J Abbott; David A X Nayagam; Elizabeth K Baglin; Jessica Kvansakul; Nick Barnes; Janine G Walker; Stephanie B Epp; Kiera A Young; Lauren N Ayton; Chi D Luu; Penelope J Allen
Journal:  Transl Vis Sci Technol       Date:  2021-08-12       Impact factor: 3.283

7.  Concept Mapping to Identify Content for a Performance-Based Measure of Low Luminance Vision-Related Activities of Daily Living.

Authors:  Sharon A Bentley; Alex A Black; Gregory P Hindmarsh; Cynthia Owsley; Joanne M Wood
Journal:  Transl Vis Sci Technol       Date:  2022-09-01       Impact factor: 3.048

8.  QD laser eyewear as a visual field aid in a visual field defect model.

Authors:  Chigusa Iyama; Yuta Shigeno; Eri Hirano; Mamoru Kamoshita; Norihiro Nagai; Misa Suzuki; Sakiko Minami; Toshihide Kurihara; Hideki Sonobe; Kazuhiro Watanabe; Hajime Shinoda; Kazuo Tsubota; Yoko Ozawa
Journal:  Sci Rep       Date:  2019-01-30       Impact factor: 4.379

9.  Enhanced Depth Navigation Through Augmented Reality Depth Mapping in Patients with Low Vision.

Authors:  Anastasios Nikolas Angelopoulos; Hossein Ameri; Debbie Mitra; Mark Humayun
Journal:  Sci Rep       Date:  2019-08-02       Impact factor: 4.379

10.  Assessing Photoreceptor Status in Retinal Dystrophies: From High-Resolution Imaging to Functional Vision.

Authors:  José-Alain Sahel; Kate Grieve; Chloé Pagot; Colas Authié; Saddek Mohand-Said; Michel Paques; Isabelle Audo; Karine Becker; Anne-Elisabeth Chaumet-Riffaud; Line Azoulay; Emmanuel Gutman; Thierry Léveillard; Christina Zeitz; Serge Picaud; Deniz Dalkara; Katia Marazova
Journal:  Am J Ophthalmol       Date:  2021-05-14       Impact factor: 5.258

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.